GFAP and amyloidosis: This result is in contrast to previous results of VIVIT, or NFAT knock‐down, in amyloid mouse models (Furman et al., 2012; Manocha et al., 2017; Sompol et al., 2017), but is comparable to our previous work in a rat traumatic brain injury model, where astrocyte‐mediated delivery of VIVIT produced several beneficial effects on neural function, without appreciably modifying GFAP levels (Furman et al., 2016).